Results from studies related to Optimer Pharmaceuticals, Inc.’s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010.
Fidaxomicin abstracts and speakers include:
“Randomized Controlled Trial (RCT) of Fidaxomicin (FDX) Versus Vancomycin (VAN) in Treatment of Recurrent Clostridium difficile Infection (CDI)”
Oral Presentation: Oliver Cornely, M.D.
Tuesday, September 14, 2010 9:00 am – 9:15 am Eastern Time
Presentation number: L1-1305 in 253A
“Clostridium difficile Strain Type as Determined by Restriction Endonuclease Analysis (REA) Typing in Two Phase III Trials of Fidaxomicin vs Vancoymcin: Treatment Outcome for the Epidemic BI/NAP1/027 Strain”
Oral Presentation: Dale N. Gerding, M.D.
Tuesday, September 14, 2010 9:15 am – 9:30 am Eastern Time
Presentation number: L1-1306 in 253A
“Correlation of the ATLAS Bedside Scoring System And Its Components With Cure and Recurrence of Clostridium difficile Infection (CDI)”
Poster Presentation: Mark A. Miller, M.D.
Tuesday, September 14, 2010 11:15 am – 1:15 pm Eastern Time
Presentation number: K-1692 in Exhibit Hall B1
“Use of Concomitant Antibiotics (CA) Has a Deleterious Effect on Outcomes During Treatment for Clostridium difficile Infection (CDI)”
Poster Presentation: Kate Mullane, M.D.
Tuesday, September 14, 2010 11:15 am – 1:15 pm Eastern Time
Presentation number: K-1695 in Exhibit Hall B1
“Comparative Susceptibilities of Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence and Failure from Patients in a Phase III trial (004) of C difficile infection (CDI)”.
Poster Presentation: Ellie J. Goldstein, M.D.
Tuesday, September 14, 2010 11:15 am – 1:15 pm Eastern Time
Presentation number: K-1691 in Exhibit Hall B1